Lakeshorebio
About Lakeshorebio
Lakeshorebio is a company was acquired by Oceanpine Capital in November 2025. Lakeshorebio has raised $170 million across 5 funding rounds from investors including Orbimed, Haitong International Securities Group and Eight Roads Ventures. The company has 573 employees as of March 31, 2024. Lakeshorebio offers products and services including Rabies Vaccine and Hepatitis Vaccine.
- Employees 573 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Lakeshore Biopharma Co., Ltd
-
Annual Revenue
$85.67 M (USD)6as on Mar 31, 2024
-
Net Profit
-$13.93 M (USD)77.2as on Mar 31, 2024
-
EBITDA
-$1.8 M (USD)94.81as on Mar 31, 2024
-
Total Equity Funding
$170 M (USD)
in 5 rounds
-
Latest Funding Round
$15 M (USD), Post-IPO
Jul 08, 2025
-
Investors
Orbimed
& 12 more
-
Employee Count
573
as on Mar 31, 2024
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lakeshorebio
Lakeshorebio is a publicly listed company on the NASDAQ with ticker symbol LSB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lakeshorebio
Lakeshorebio offers a comprehensive portfolio of products and services, including Rabies Vaccine and Hepatitis Vaccine.
The vaccine is produced using Vero cells for infectious disease prevention
Vaccines for hepatitis are developed using CHO cells and other methods for immune protection
Funding Insights of Lakeshorebio
Lakeshorebio has successfully raised a total of $170M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $15.0M
- First Round First Round
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Post-IPO - Lakeshorebio | Valuation |
investors |
|
| Feb, 2024 | Amount | Post-IPO - Lakeshorebio | Valuation |
investors |
|
| Mar, 2022 | Amount | Series B - Lakeshorebio | Valuation | Legend Capital |
Investors in Lakeshorebio
Lakeshorebio has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Haitong International Securities Group and Eight Roads Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture Capital firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Venture capital investment and global platform support for startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lakeshorebio
Financial Statements - Lakeshorebio
Lakeshorebio Comparisons
Competitors of Lakeshorebio
Frequently Asked Questions about Lakeshorebio
Lakeshorebio is a funded company, having raised a total of $170M across 5 funding rounds to date. The company's 1st funding round was a Series B of $40M, raised on Jun 01, 2012.
As of Mar 31, 2024, the latest employee count at Lakeshorebio is 573.
Annual revenue of Lakeshorebio is $85.67M as on Mar 31, 2024.
Research, development, and production of vaccines targeting infectious diseases are conducted by Lakeshorebio, a biotechnology firm. PIKA immune modulation technology is utilized in these efforts. The portfolio includes rabies and hepatitis B vaccines, manufactured via various cell lines. Operations focus on immunotherapeutics, with the company maintaining public trading status. The domain lakeshorebio.com is associated with these activities.
Lakeshorebio offers Rabies Vaccine and Hepatitis Vaccine.
Yes, Lakeshorebio is publicly traded on NASDAQ under the ticker symbol LSB.
Lakeshorebio has 13 investors. Key investors include Orbimed, Haitong International Securities Group, Eight Roads Ventures, Legend Capital, and XS Xinsheng.
The ticker symbol of Lakeshorebio is LSB on NASDAQ.